The change will expand access to the diabetes and weight-loss drugs. But it will also complicate the future of compounded ...

Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit ...

After nearly two years, federal regulators announced the shortage of the active ingredient in Mounjaro and Zepbound has been ...

The roadmap suggests those with the greatest clinical need will get priority access, according to the NHS national medical ...

GLP-1 weight-loss drugs Mounjaro and Zepbound have been removed from the Food and Drug Administration's (FDA) shortage list. ...

The US Food and Drug Administration (FDA) has declared an end to the shortage of tirzepatide, the active ingredient in Eli ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 568.82% and ...

Momentum investing is based on the idea that stocks that have risen recently will tend to keep rising and that stocks that ...

Hims & Hers Health Inc (NYSE:HIMS) shares are trading higher Monday. The company is set to join to the S&P SmallCap 600 this ...

While Mounjaro was cleared for use in England last year, Lilly put its launch on hold until its pre-filled injection device, ...

The NHS plans to roll out Mounjaro, a weight-loss jab that can help users lose up to a quarter of their body weight, making it more potent than Ozempic. Anna Magee explains how to choose the best opti ...

Tirzepatide injection (Zepbound, Mounjaro) is officially off the FDA's drug shortage list, meaning compounders can no longer prepare and dispense the drug.